CRUK, ECMC and UK Radiopharmacy Group Taskforce (CERT)

Tab Group

Overview

As a primary interface between the radiopharmacy community and regulatory authorities, the group aims to provide a common understanding of regulatory requirements for clinical trials that involve radiopharmaceuticals.

Mission Statement

CERT has the key aim of acting as the primary interface between the radiopharmacy community and regulatory authorities.

The emphasis is on creating a common understanding of the regulatory requirements for the development and delivery of clinical trials that involve radiopharmaceuticals, primarily at ECMCs but also all other relevant UK clinical trial units.

CERT actively influences clinical trial regulations and guidelines to take into account the specialised nature of radiopharmacy clinical trials. This helps ensure that coherent implementation into practice happens across the UK radiopharmacy community.

Remit

Steer the activities of CERT by identifying priorities for the development of the Taskforce
Understand and influence the clinical trial regulations, and how they can be uniformly applied to clinical trials needing radiopharmacy involvement
Provide advice on interfacing with industry and the regulators with respect to radiopharmacy activities in clinical trials
Ensure coherent networking within the radiopharmacy community
Facilitate expertise and knowledge sharing between ECMCs and throughout the UK research radiopharmacy community
Identify options and practical solutions for sharing best practise practice and knowledge
Discuss scientific, strategic and resourcing issues relating to radiopharmacy in early phase cancer trials
Identify priority areas where insufficient or out of date guidance exists and develop new or updated guidelines
Raise the profile of early phase cancer trials involving molecularly targeted radiopharmaceuticals
Implement innovative approaches to ensure radiopharmacy support for trials can be delivered more consistently and effectively across the UK
Assist research groups in the development and completion of clinical trials involving radiopharmaceuticals

Steering Committee Members

Chair

Kim Orchard (University Hospital Southampton)

Members
Pei-San Chan (Royal Free Hospital)
Margaret Cooper (Royal Liverpool Hospital)
Jilly Croasdale (Birmingham City Hospital NHS Trust)
Glenn Flux (Institute of Cancer Research)
Adam McMahon (University of Manchester)
Sam Mowbray (University of Manchester)
Maria Palmer (United Bristol Healthcare NHS Trust)
James Ritchie (Cancer Research UK)
Julie Silvester (Cancer Research UK)
Nigel Westwood (Cancer Research UK)

Resources

No Resources found

CRUK, ECMC and UK Radiopharmacy Group Taskforce (CERT)

You are here

Tab Group